166 related articles for article (PubMed ID: 21800344)
1. Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation.
Urtasun R; Latasa MU; Demartis MI; Balzani S; Goñi S; Garcia-Irigoyen O; Elizalde M; Azcona M; Pascale RM; Feo F; Bioulac-Sage P; Balabaud C; Muntané J; Prieto J; Berasain C; Avila MA
Hepatology; 2011 Dec; 54(6):2149-58. PubMed ID: 21800344
[TBL] [Abstract][Full Text] [Related]
2. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
Wahl K; Siegemund M; Lehner F; Vondran F; Nüssler A; Länger F; Krech T; Kontermann R; Manns MP; Schulze-Osthoff K; Pfizenmaier K; Bantel H
Hepatology; 2013 Feb; 57(2):625-36. PubMed ID: 22991197
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma.
Mazzocca A; Fransvea E; Dituri F; Lupo L; Antonaci S; Giannelli G
Hepatology; 2010 Feb; 51(2):523-34. PubMed ID: 19821534
[TBL] [Abstract][Full Text] [Related]
4. S1P Stimulates Proliferation by Upregulating CTGF Expression through S1PR2-Mediated YAP Activation.
Cheng JC; Wang EY; Yi Y; Thakur A; Tsai SH; Hoodless PA
Mol Cancer Res; 2018 Oct; 16(10):1543-1555. PubMed ID: 29903770
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the effect of targeting the epidermal growth factor receptor on TGF-β-induced-apoptosis in human hepatocellular carcinoma cells.
Caja L; Sancho P; Bertran E; Fabregat I
J Hepatol; 2011 Aug; 55(2):351-8. PubMed ID: 21147185
[TBL] [Abstract][Full Text] [Related]
6. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients.
Wang RY; Chen L; Chen HY; Hu L; Li L; Sun HY; Jiang F; Zhao J; Liu GM; Tang J; Chen CY; Yang YC; Chang YX; Liu H; Zhang J; Yang Y; Huang G; Shen F; Wu MC; Zhou WP; Wang HY
Gastroenterology; 2013 Dec; 145(6):1436-48.e1-12. PubMed ID: 23933603
[TBL] [Abstract][Full Text] [Related]
7. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo.
Jia XQ; Cheng HQ; Li H; Zhu Y; Li YH; Feng ZQ; Zhang JP
Chin Med J (Engl); 2011 Nov; 124(22):3794-9. PubMed ID: 22340243
[TBL] [Abstract][Full Text] [Related]
9. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
[TBL] [Abstract][Full Text] [Related]
11. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis.
Nussbaum T; Samarin J; Ehemann V; Bissinger M; Ryschich E; Khamidjanov A; Yu X; Gretz N; Schirmacher P; Breuhahn K
Hepatology; 2008 Jul; 48(1):146-56. PubMed ID: 18537183
[TBL] [Abstract][Full Text] [Related]
12. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
[TBL] [Abstract][Full Text] [Related]
13. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.
Marquard S; Thomann S; Weiler SME; Bissinger M; Lutz T; Sticht C; Tóth M; de la Torre C; Gretz N; Straub BK; Marquardt J; Schirmacher P; Breuhahn K
Cell Commun Signal; 2020 Oct; 18(1):166. PubMed ID: 33097058
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines.
Yamanaka T; Shiraki K; Sugimoto K; Ito T; Fujikawa K; Ito M; Takase K; Moriyama M; Nakano T; Suzuki A
Hepatology; 2000 Sep; 32(3):482-90. PubMed ID: 10960439
[TBL] [Abstract][Full Text] [Related]
15. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells.
Castillo J; Erroba E; Perugorría MJ; Santamaría M; Lee DC; Prieto J; Avila MA; Berasain C
Cancer Res; 2006 Jun; 66(12):6129-38. PubMed ID: 16778186
[TBL] [Abstract][Full Text] [Related]
16. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
17. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma.
Hsieh SY; He JR; Hsu CY; Chen WJ; Bera R; Lin KY; Shih TC; Yu MC; Lin YJ; Chang CJ; Weng WH; Huang SF
Hepatology; 2011 Feb; 53(2):504-16. PubMed ID: 21246584
[TBL] [Abstract][Full Text] [Related]
18. Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance.
Zeng ZJ; Yang LY; Ding X; Wang W
World J Gastroenterol; 2004 Dec; 10(23):3414-8. PubMed ID: 15526358
[TBL] [Abstract][Full Text] [Related]
19. shRNA-mediated silencing of Gli2 gene inhibits proliferation and sensitizes human hepatocellular carcinoma cells towards TRAIL-induced apoptosis.
Zhang D; Liu J; Wang Y; Chen J; Chen T
J Cell Biochem; 2011 Nov; 112(11):3140-50. PubMed ID: 21695716
[TBL] [Abstract][Full Text] [Related]
20. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
